I'm not going to link to it because non-subscribers only get 10 free articles per month, but NY Times had an article about how there are so mahy CAR-T drug clinical trials going on, they're having trouble getting patients to fill them.
But what was interesting was -- they said that NOVEL drugs had a much easier time getting patients. The CAR-T drugs are all so similar that they're competing for the same population. The novel drugs attract different kinds of patients.
Plus let's remember that the side effects with the CAR-T drugs have killed some people.
Kevetrin, of course, is a NOVEL drug.
But what was interesting was -- they said that NOVEL drugs had a much easier time getting patients. The CAR-T drugs are all so similar that they're competing for the same population. The novel drugs attract different kinds of patients.
Plus let's remember that the side effects with the CAR-T drugs have killed some people.
Kevetrin, of course, is a NOVEL drug.
5